Because METTL7B enhanced the expression of essential ROS-scavenging enzymes, SOD1, GPX4 and HMOX1 as well as their enzymatic activities [33–35], it is worthy to explore whether METTL7B could promote resistance to other anti-cancer reagents in addition to TKIs in the future. The gene discussed is SOD1; the disease is cancer.